HighLife Raises €80M for Heart Valves

French startup HighLife raised over $90 million (about €80 million) to commercialize its catheter-based mitral valve replacement in Europe and fund clinical trials in the United States. The round was led by Sofinnova Partners, Andera Partners, Supernova Invest and Mérieux Equity Partners. HighLife obtained CE marking in January and for its Clarity valve in July.